A phase II trial of dacarbazine (DTIC) and bevacizumab in patients with metastatic melanoma

8579 Background: Dacarbazine (DTIC) has been approved for treating metastatic melanoma in the 1970s, and as a single agent gives a response rate of about 20%. There have been efforts to ameliorate ...